Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

ESMO 35: High response rates seen in Phase-III trial of chemotherapy, new drug and stem cells in myeloma

ESMO 35: High response rates seen in Phase-III trial of chemotherapy, new drug and stem cells in myeloma

ESMO 35: Investigational ovarian cancer drug shows promise against platinum resistant disease in Phase-II trial

ESMO 35: Investigational ovarian cancer drug shows promise against platinum resistant disease in Phase-II trial

ESMO 35: Identifying subsets of patients who will respond to subsequent lines of chemotherapy

ESMO 35: Identifying subsets of patients who will respond to subsequent lines of chemotherapy

ESMO 35: Study reveals cancer-linked epigenetic effects of smoking

ESMO 35: Study reveals cancer-linked epigenetic effects of smoking

ESMO 35: Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

ESMO 35: Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

ESMO 35: New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

ESMO 35: New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

$ESMO 35: Surgical technique relives painful spine fractures in patients with metastatic cancer$

ESMO 35: Surgical technique relives painful spine fractures in patients with metastatic cancer

What we are reading this week at the European Institute of Oncology

What we are reading this week at the European Institute of Oncology

Intrauterine devices (IUDs) can be used to treat endometrial cancer

Intrauterine devices (IUDs) can be used to treat endometrial cancer

MEPs and health professionals call for urgent action to tackle chronic diseases

MEPs and health professionals call for urgent action to tackle chronic diseases

More from ecancer